Cargando…
Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer
SIMPLE SUMMARY: Personalized breast cancer treatment with targeted therapy (e.g., tamoxifen or PI3K inhibitors) requires identification of responder patients. Phenotypical heterogeneity within the primary, and between primary tumor and metastases, may however interfere with response to therapy, if b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002348/ https://www.ncbi.nlm.nih.gov/pubmed/33809754 http://dx.doi.org/10.3390/cancers13061345 |